Vanguard Group’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-292,664
| Closed | -$1.85M | – | 4608 |
|
|
2022
Q4 | $1.85M | Sell |
292,664
-19,944
| -6% | -$110K | ﹤0.01% | 3685 |
|
|
2022
Q3 | $1.6M | Sell |
312,608
-576,645
| -65% | -$3.62M | ﹤0.01% | 3843 |
|
|
2022
Q2 | $5.57M | Buy |
889,253
+290,816
| +49% | +$979K | ﹤0.01% | 3326 |
|
|
2022
Q1 | $2.12M | Sell |
598,437
-149,263
| -20% | -$551K | ﹤0.01% | 3931 |
|
|
2021
Q4 | $3.75M | Buy |
747,700
+3,077
| +0.4% | +$18.6K | ﹤0.01% | 3772 |
|
|
2021
Q3 | $5.45M | Sell |
744,623
-28,592
| -4% | -$196K | ﹤0.01% | 3601 |
|
|
2021
Q2 | $6.64M | Buy |
773,215
+244,726
| +46% | +$2.09M | ﹤0.01% | 3429 |
|
|
2021
Q1 | $5.72M | Buy |
528,489
+140,441
| +36% | +$1.36M | ﹤0.01% | 3458 |
|
|
2020
Q4 | $3.83M | Buy |
388,048
+281,851
| +265% | +$1.85M | ﹤0.01% | 3477 |
|
|
2020
Q3 | $569K | Sell |
106,197
-4,127
| -4% | -$24.7K | ﹤0.01% | 3790 |
|
|
2020
Q2 | $649K | Sell |
110,324
-1,807
| -2% | -$10.4K | ﹤0.01% | 3708 |
|
|
2020
Q1 | $417K | Hold |
112,131
| – | – | ﹤0.01% | 3708 |
|
|
2019
Q4 | $709K | Hold |
112,131
| – | – | ﹤0.01% | 3719 |
|
|
2019
Q3 | $1.57M | Sell |
112,131
-13,976
| -11% | -$230K | ﹤0.01% | 3528 |
|
|
2019
Q2 | $1.86M | Sell |
126,107
-12,256
| -9% | -$328K | ﹤0.01% | 3495 |
|
|
2019
Q1 | $5.81M | Buy |
138,363
+83
| +0.1% | +$3.5K | ﹤0.01% | 3084 |
|
|
2018
Q4 | $5.75M | Buy |
138,280
+983
| +0.7% | +$44.2K | ﹤0.01% | 3023 |
|
|
2018
Q3 | $6.62M | Buy |
137,297
+35,433
| +35% | +$1.77M | ﹤0.01% | 3130 |
|
|
2018
Q2 | $4.83M | Buy |
101,864
+11,661
| +13% | +$647K | ﹤0.01% | 3226 |
|
|
2018
Q1 | $5.55M | Buy |
90,203
+22,424
| +33% | +$1.18M | ﹤0.01% | 3099 |
|
|
2017
Q4 | $3.65M | Buy |
67,779
+19,781
| +41% | +$1.18M | ﹤0.01% | 3248 |
|
|
2017
Q3 | $3.23M | Buy |
47,998
+33,347
| +228% | +$1.91M | ﹤0.01% | 3267 |
|
|
2017
Q2 | $794K | Buy |
+14,651
| New | +$679K | ﹤0.01% | 3623 |
|
Vanguard Group's FSTX Position: Q1 2023 in Review
Vanguard Group sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 292,664 shares — an estimated $1.85M sold.
Vanguard Group first reported a position in FSTX in Q2 2017 and held it in 23 quarters. The position peaked at $6.64M in Q2 2021. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.
- Vanguard Group reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Vanguard Group sold 292,664 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.85M.
- Vanguard Group first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2017 and held it in 23 quarters.
- Vanguard Group's F-star Therapeutics, Inc. Common Stock position peaked at $6.64M in Q2 2021.
- 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.
Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.